Fingerprint
Dive into the research topics of 'Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell long cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell long cancer
E Fokkema, HJM Groen*, DRA Uges, C Weil, IE Smith
*Corresponding author for this work
Research output: Contribution to journal › Article › Academic › peer-review
53
Citations
(Scopus)